Day | Untreated control | Lotilaner | Comparison | ||||
---|---|---|---|---|---|---|---|
Mean | Range | Mean | Range | Geometric (arithmetic) mean efficacy (%) | |||
Study 1 | 2 | 33.6 (35.0) | 22–48 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 32.0, P < 0.0001 |
9 | 20.8 (23.0) | 11–42 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 18.7, P < 0.0001 | |
16 | 20.0 (24.0) | 5–44 | 0.1 (0.1) | 0–1 | 99.5 (99.5) | t (7) = 11.8, P < 0.0001 | |
23 | 21.5 (24.3) | 9–46 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 16.7, P < 0.0001 | |
30 | 12.7 (18.3) | 0–38 | 0.1 (0.1) | 0–1 | 99.3 (99.3) | t (7) = 6.2, P = 0.0004 | |
37 | 14.5 (19.6) | 2–42 | 0.3 (0.5) | 0–3 | 98.0 (97.5) | t (7) = 7.2, P = 0.0002 | |
Study 2 | 2 | 24.7 (25.0) | 18–30 | 0.0 (0.0) | 0–0 | 100 (100) | t (14) = 53.5, P < 0.0001 |
9 | 7.1 (9.0) | 3–23 | 0.0 (0.0) | 0–0 | na | na | |
16 | 20.3 (21.9) | 10–35 | 0.0 (0.0) | 0–0 | 100 (100) | t (13) = 24.0, P < 0.0001 | |
23 | 29.4 (30.1) | 22–41 | 0.0 (0.0) | 0–0 | 100 (100) | t (13) = 42.5, P < 0.0001 | |
30 | 21.9 (22.3) | 15–28 | 0.1 (0.1) | 0–1 | 99.6 (99.4) | t (14) = 27.6, P < 0.0001 | |
37 | 29.6 (30.5) | 17–40 | 0.0 (0.0) | 0–0 | 100 (100) | t (13) = 39.5, P < 0.0001 | |
Study 3 | 2 | 16.6 (17.6) | 11–36 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 23.6, P < 0.0001 |
9 | 14.2 (20.6) | 0–41 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 6.5, P = 0.0003 | |
16 | 21.3 (22.1) | 13–33 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 30.8, P < 0.0001 | |
23 | 26.8 (27.8) | 18–41 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 34.5, P < 0.0001 | |
30 | 31.8 (32.1) | 25–39 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 70.1, P < 0.0001 | |
37 | 19.2 (21.3) | 9–36 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 17.7, P < 0.0001 |